DBV Technologies S.A. experienced a significant price increase of 44.61%, reaching a 52-week high, following the announcement of positive results from its Phase 3 VITESSE trial for the VIASKIN Peanut patch.
The surge is attributed to the successful Phase 3 VITESSE trial results for the VIASKIN Peanut patch, which demonstrated a 46.6% response rate among children, significantly higher than the 14.8% in the placebo group. This success not only highlights the clinical relevance of the treatment but also sets the stage for a Biologics License Application (BLA) submission to the FDA in early 2026, with expectations for priority review.
This positive trial outcome has reinvigorated investor interest in DBV Technologies, reflecting optimism about the company's future in the peanut allergy treatment market, especially given the favorable safety profile and the potential for substantial funding to support further development.
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 46.40 USD with a low forecast of 40.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 46.40 USD with a low forecast of 40.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.770
Low
40.00
Averages
46.40
High
51.00
Current: 23.770
Low
40.00
Averages
46.40
High
51.00
Cantor Fitzgerald
Kristen Kluska
upgrade
$42 -> $48
2025-12-17
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$42 -> $48
AI Analysis
2025-12-17
upgrade
Reason
Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on DBV Technologies to $48 from $42 and keeps an Overweight rating on the shares. DBV Technologies announced successful results from the Phase 3 VITESSE study of VIASKIN, with open-label extension enrollment trends in-line with previous studies and compliance "quite high" at over 96%, the analyst tells investors in a research note. Cantor is confident that these data check off the final box for a BLA submission in this patient population.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$35 -> $40
2025-12-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$35 -> $40
2025-12-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on DBV Technologies to $40 from $35 and keeps a Buy rating on the shares. The company's Phase 3 VITESSE trial in 4-7 year old peanut-allergic children "represents a clear execution win that we believe materially de-risks the Viaskin program," the analyst tells investors in a research note. The firm says the positive readout supports an application submission in the first half of 2026 and strengthens its confidence in a straightforward regulatory path.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DBVT
Unlock Now
Citizens
Outperform
maintain
$21 -> $45
2025-12-17
Reason
Citizens
Price Target
$21 -> $45
2025-12-17
maintain
Outperform
Reason
Citizens raised the firm's price target on DBV Technologies to $45 from $21 and keeps an Outperform rating on the shares. The firm was "optimistic" going into the Phase 3 VITESSE trial and was "pleased" to see a 46.6% treatment effect vs. 14.8% for placebo, the analyst tells investors in a research note. VITESSE supports a BLA submission in the first half of 2026, which may be eligible for Priority Review, and the success in VITESSE triggers an acceleration of the exercise price of $181M in outstanding warrants, bringing in a cash infusion, which management estimates is sufficient to fund the potential launch in 4-7 year olds, the firm says.
Guggenheim
Buy
upgrade
$35 -> $51
2025-12-17
Reason
Guggenheim
Price Target
$35 -> $51
2025-12-17
upgrade
Buy
Reason
Guggenheim raised the firm's price target on DBV Technologies to $51 from $35 and keeps a Buy rating on the shares after the "highly positive" topline readout from the Phase 3 VITESSE study of the Viaskin peanut patch in children with peanut allergy. The firm is "very pleased" with the VITESSE results and looks forward to the continued development towards a commercial launch, the analyst tells investors.
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
